In this issue:
Safety of bimekizumab in plaque psoriasis
Deucravacitinib for scalp psoriasis
Secukinumab dose reduction in psoriasis
Long-term drug survival, effectiveness and safety of ixekizumab
Deucravacitinib in plaque, erythrodermic, and generalised pustular psoriasis
TNF-α and IL-12/23 inhibitors and risk of MACE and all-cause mortality
Real-world insights for psoriasis
Association between psoriasis and cardiometabolic comorbidities
Please login below to download this issue (PDF)